New nasal spray COVID-19 booster could replace needles
NCT ID NCT06821126
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a new intranasal (nose spray) COVID-19 booster vaccine, LVT-001, with the standard mRNA booster shot in 238 healthy adults. The goal is to see if the nasal vaccine is safe and triggers a strong immune response, especially in the nose and throat where the virus first enters. The trial has two phases: first, testing different doses for safety, then comparing the best dose to the mRNA booster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LVT-001 (intranasal COVID-19 vaccine) and Pfizer-BioNTech mRNA vaccine (Cormirnaty)
What this could lead to
If successful, this could provide a needle-free, easier-to-take booster option that may better protect against COVID-19 at the nose and mouth, where the virus enters.
What could go wrong
This is an early Phase I/II trial with only 238 participants, so results may not apply to everyone. The intranasal vaccine is first-in-human, so safety and effectiveness are still unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP - Hôpital Cochin - Centre d'Investigation Clinique de Vaccinologie Cochin-Pasteur 1417
NOT_YET_RECRUITINGParis, 75679, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHRU de Tours - Centre d'Investigation Clinique 1415
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Dijon Bourgogne - Centre d'Investigation Clinique 1432
NOT_YET_RECRUITINGDijon, 21079, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Etienne - Service des Maladies Infectieuses
NOT_YET_RECRUITINGSaint-Priest-en-Jarez, 42270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCL - Hôpital de la Croix-Rousse - Service des Maladies Infectieuses et Tropicales
NOT_YET_RECRUITINGLyon, 69004, France
Contact Phone: •••-•••-•••• Email: •••••@•••••